Revisiting the design of phase III clinical trials of antimalarial drugs for uncomplicated Plasmodium falciparum malaria.
Borrmann
Steffen
S
Steffen Borrmann is with the Kenya Medical Research Institute, Wellcome Trust Research Programme, Centre for Geographical Medicine Research, Coast, Kilifi, Kenya. sborrmann@kilifi.kemri-wellcome.org
Peto
Tim
T
Snow
Robert W
RW
Gutteridge
Win
W
White
Nicholas J
NJ
D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000401:mortality / Q000469:parasitology / Q000517:prevention & control; D010963:Plasmodium falciparum / Q000187:drug effects; D055502:Secondary Prevention; D016019:Survival Analysis; D016896:Treatment Outcome
D000962:Antimalarials